Radioembolization of Liver Tumors With Yttrium-90 Microspheres

Seminars in Nuclear Medicine

Volumn 40, Issue 2, 2010, Pages 105-121

  Ahmadzadehfar, Hojjat ^a   Biersack, Hans Jürgen ^a   Ezziddin, Samer ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANALGESIC AGENT; BEVACIZUMAB; CAPECITABINE; CORTICOSTEROID; DEXAMETHASONE; FLOXURIDINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GALLIUM EDETATE GA 68; GEMCITABINE; GRANISETRON; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; MACROSALB TC 99M; MICROSPHERE; OMEPRAZOLE; ONDANSETRON; OXALIPLATIN; PANTOPRAZOLE; PENTOXIFYLLINE; PETHIDINE; PREDNISOLONE; RESIN; STEROID; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; ARTIFICIAL EMBOLISM; BILE DUCT DISEASE; CANCER CHEMOTHERAPY; CATHETERIZATION; CHOLECYSTITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM ULCER; DOSIMETRY; DRUG DOSE REDUCTION; DRUG PENETRATION; EDEMA; FOLLOW UP; FUNCTIONAL ASSESSMENT; GASTRODUODENAL ULCER; GOLD STANDARD; HEPATITIS; HUMAN; IMAGING; LIVER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER PAIN; LIVER TUMOR; METHODOLOGY; MORPHOLOGY; NAUSEA; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; PAIN; PANCREAS CANCER; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; RADIOEMBOLIZATION; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

HUMANS; LIVER NEOPLASMS; MICROSPHERES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; YTTRIUM;

EID: 74849103358     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.11.001     Document Type: Review

References (108)

1. Salem R., and Thurston K.G. Radioembolization with 90Yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 17 (2006) 1251-1278
2. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239 (2004) 818-825 discussion 825-827
3. Jarnagin W.R., Gonen M., Fong Y., et al. Improvement in perioperative outcome after hepatic resection: Analysis of 1,803 consecutive cases over the past decade. Ann Surg 236 (2002) 397-406 discussion 406-397
4. Mulcahy M.F., Lewandowski R.J., Ibrahim S.M., et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115 (2009) 1849-1858
5. Kennedy A., Nag S., Salem R., et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68 (2007) 13-23
6. Dawson L.A., Normolle D., Balter J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53 (2002) 810-821
7. Greco C., Catalano G., Di Grazia A., et al. Radiotherapy of liver malignancies. From whole liver irradiation to stereotactic hypofractionated radiotherapy. Tumori 90 (2004) 73-79
8. Murthy R., Nunez R., Szklaruk J., et al. Yttrium-90 microsphere therapy for hepatic malignancy: Devices, indications, technical considerations, and potential complications. Radiographics 25 suppl 1 (2005) S41-S55
9. Campbell A.M., Bailey I.H., and Burton M.A. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 45 (2000) 1023-1033
10. Lien W.M., and Ackerman N.B. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery 68 (1970) 334-340
11. Sirtex Medical Limited. Sirtex medical training manual, training program physicians and institutions. Australia. http://www.sirtex.com/usa/_data/page/549/TRN-US-0320for20US1.pdf Accessed October 16, 2007
12. Sarfaraz M., Kennedy A.S., Lodge M.A., et al. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys 31 (2004) 2449-2453
13. Sarfaraz M., Kennedy A.S., Cao Z.J., et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys 30 (2003) 199-203
14. Dancey J.E., Shepherd F.A., Paul K., et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41 (2000) 1673-1681
15. Stubbs R.S., Cannan R.J., and Mitchell A.W. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology 48 (2001) 333-337
16. Lawrence T.S., Robertson J.M., Anscher M.S., et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31 (1995) 1237-1248
17. Salem R., Lewandowski R., Roberts C., et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 15 (2004) 335-345
18. Lewandowski R.J., Thurston K.G., Goin J.E., et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: Response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16 (2005) 1641-1651
19. Salem R., Lewandowski R.J., Atassi B., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival. J Vasc Interv Radiol 16 (2005) 1627-1639
20. Delbeke D., Vitola J.V., Sandler M.P., et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 38 (1997) 1196-1201
21. Arulampalam T.H., Francis D.L., Visvikis D., et al. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol 30 (2004) 286-291
22. Bohm B., Voth M., Geoghegan J., et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 130 (2004) 266-272
23. Ogunbiyi O.A., Flanagan F.L., Dehdashti F., et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann Surg Oncol 4 (1997) 613-620
24. Herbertson R.A., Scarsbrook A.F., Lee S.T., et al. Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clin Radiol 64 (2009) 225-237
25. MacManus M., Nestle U., Rosenzweig K.E., et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 91 (2009) 85-94
26. Yang M., Martin D.R., Karabulut N., et al. Comparison of MR and PET imaging for the evaluation of liver metastases. J Magn Reson Imaging 17 (2003) 343-349
27. Jakobs T. Radiological detection and assessment of tumor response. In: Bilbao J.I., and Reiser M.F. (Eds). Liver Radioembolization with 90Y Microspheres (2008), Springer, New York, NY 93-106
28. Roedl J.B., Halpern E.F., Colen R.R., et al. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol 11 (2009) 54-60
29. Ramirez de Molina A., Rodriguez-Gonzalez A., Gutierrez R., et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296 (2002) 580-583
30. Hara T., Kosaka N., and Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39 (1998) 990-995
31. Kwee S.A., DeGrado T.R., Talbot J.N., et al. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 37 (2007) 420-428
32. Talbot J.N., Gutman F., Fartoux L., et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: Preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 33 (2006) 1285-1289
33. Yamamoto Y., Nishiyama Y., Kameyama R., et al. Detection of hepatocellular carcinoma using 11C-choline PET: Comparison with 18F-FDG PET. J Nucl Med 49 (2008) 1245-1248
34. Covey A.M., Brody L.A., Maluccio M.A., et al. Variant hepatic arterial anatomy revisited: Digital subtraction angiography performed in 600 patients. Radiology 224 (2002) 542-547
35. Liu D.M., Salem R., Bui J.T., et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16 (2005) 911-935
36. Leung T.W., Lau W.Y., Ho S.K., et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33 (1995) 919-924
37. Lewandowski R.J., Sato K.T., Atassi B., et al. Radioembolization with 90Y microspheres: Angiographic and technical considerations. Cardiovasc Intervent Radiol 30 (2007) 571-592
38. Ahmadzadehfar H., Sabet A., Biermann K., et al. The significance of Tc-99m-MAA SPECT-CT liver perfusion imaging in treatment planning for yttrium 90 microsphere selective internal radiation treatment. [meeting abstracts 2]. J Nucl Med 50 (2009) 1662
39. Lau W.Y., Ho S., Leung T.W., et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40 (1998) 583-592
40. TheraSphere Yttrium-90 Glass Microspheres Users Manual. MDS Nordion, Ottawa, Ontario, Canada
41. Salem R., and Hunter R.D. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: A review. Int J Radiat Oncol Biol Phys 66 suppl 2 (2006) S83-S88
42. Hamami M.E., Poeppel T.D., Muller S., et al. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med 50 (2009) 688-692
43. Kennedy A.S., Coldwell D., Nutting C., et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys 65 (2006) 412-425
44. Moroz P., Anderson J.E., Van Hazel G., et al. Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol 78 (2001) 248-252
45. Lewandowski R.J., and Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 23 (2006) 64-72
46. Murthy R., Habbu A., and Salem R. Trans-arterial hepatic radioembolisation of yttrium-90 microspheres. Biomed Imaging Interv J 2 (2006) e43
47. Riaz A., Lewandowski R.J., Kulik L.M., et al. Complications following radioembolization with yttrium-90 microspheres: A comprehensive literature review. J Vasc Interv Radiol 20 (2009) 1121-1130
48. Fabbri C., Sarti G., Cremonesi M., et al. Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm 24 (2009) 145-154
49. Minarik D., Sjogreen Gleisner K., and Ljungberg M. Evaluation of quantitative (90)Y SPECT based on experimental phantom studies. Phys Med Biol 53 (2008) 5689-5703
50. Murthy R., Brown D.B., Salem R., et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18 (2007) 553-562
51. Carretero C., Munoz-Navas M., Betes M., et al. Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 102 (2007) 1216-1220
52. Salem R., Parikh P., Atassi B., et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 31 (2008) 431-438
53. Leung W.T., Lau W.Y., Ho S.K., et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med 35 (1994) 70-73
54. Yip D., Allen R., Ashton C., et al. Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. J Gastroenterol Hepatol 19 (2004) 347-349
55. Vente M.A., Wondergem M., van der Tweel I., et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: A structured meta-analysis. Eur Radiol 19 (2009) 951-959
56. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities. J Vasc Interv Radiol 16 2 Pt. 1 (2005) 205-213
57. Ingold J.A., Reed G.B., Kaplan H.S., et al. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93 (1965) 200-208
58. Fox R.A., Klemp P.F., Egan G., et al. Dose distribution following selective internal radiation therapy. Int J Radiat Oncol Biol Phys 21 (1991) 463-467
59. Sangro B., Bilbao J.I., Boan J., et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66 (2006) 792-800
60. Kennedy A.S., Nutting C., Jakobs T., et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 27 (2009) 682-690
61. Young J.Y., Rhee T.K., Atassi B., et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 18 (2007) 1375-1382
62. Toohey R.E., Stabin M.G., and Watson E.E. The AAPM/RSNA physics tutorial for residents: Internal radiation dosimetry: Principles and applications. Radiographics 20 (2000) 533-546 quiz 531-532
63. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: A risk-stratification analysis. J Vasc Interv Radiol 16 2 Pt. 1 (2005) 195-203
64. Hoffmann R., Bilbao J.I., Jakobs T., et al. Complications and side effects. In: Bilbao J.I., and Reiser M.F. (Eds). Liver Radioembolization with 90Y Microspheres (2008), Springer, New York, NY 139-146
65. Kennedy A.S., McNeillie P., Dezarn W.A., et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74 (2009) 1494-1500
66. Senzolo M., Germani G., Cholongitas E., et al. Veno occlusive disease: Update on clinical management. World J Gastroenterol 13 (2007) 3918-3924
67. Bayraktar U.D., Seren S., and Bayraktar Y. Hepatic venous outflow obstruction: Three similar syndromes. World J Gastroenterol 13 (2007) 1912-1927
68. Chopra R., Eaton J.D., Grassi A., et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol 111 (2000) 1122-1129
69. Atassi B., Bangash A.K., Lewandowski R.J., et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol 19 (2008) 691-697
70. Szyszko T., Al-Nahhas A., Tait P., et al. Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nucl Med Commun 28 (2007) 21-24
71. Lewandowski R.J., Wang D., Gehl J., et al. A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. J Vasc Interv Radiol 18 (2007) 1249-1257
72. Tran L.N., Brown M.S., Goldin J.G., et al. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Acad Radiol 11 (2004) 1355-1360
73. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
74. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
75. Therasse P., Eisenhauer E.A., Verweij J., et al. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 42 (2006) 1031-1039
76. Wahl R.L., Zasadny K., Helvie M., et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11 (1993) 2101-2111
77. Belton A.L., Saini S., Liebermann K., et al. Tumour size measurement in an oncology clinical trial: Comparison between off-site and on-site measurements. Clin Radiol 58 (2003) 311-314
78. Marn C.S., Andrews J.C., Francis I.R., et al. Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings. Radiology 187 (1993) 125-128
79. Tutt A.N., Plunkett T.A., Barrington S.F., et al. The role of positron emission tomography in the management of colorectal cancer. Colorectal Dis 6 (2004) 2-9
80. Bienert M., McCook B., Carr B.I., et al. Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging 32 (2005) 723
81. Bienert M., McCook B., Carr B.I., et al. 90Y microsphere treatment of unresectable liver metastases: Changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 32 (2005) 778-787
82. Selzner M., Hany T.F., Wildbrett P., et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg 240 (2004) 1027-1034 discussion 1035-1036
83. Wong C.Y., Salem R., Raman S., et al. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: A comparison with CT or MRI. Eur J Nucl Med Mol Imaging 29 (2002) 815-820
84. Wong C.Y., Salem R., Qing F., et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: Comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 45 (2004) 1892-1897
85. Morikawa M., Demura Y., Ishizaki T., et al. The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax. J Nucl Med 50 (2009) 81-87
86. Gray B., Van Hazel G., Buck M., et al. Treatment of colorectal liver metastases with SIR-Spheres plus chemotherapy. GI Cancer 3 (2000) 249-257
87. Gray B., Van Hazel G., Hope M., et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12 (2001) 1711-1720
88. Stubbs R.S., O'Brien I., and Correia M.M. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: Single-centre experience with 100 patients. ANZ J Surg 76 (2006) 696-703
89. Van Hazel G., Blackwell A., Anderson J., et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88 (2004) 78-85
90. Sato K.T., Lewandowski R.J., Mulcahy M.F., et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-Safety, efficacy, and survival. Radiology 247 (2008) 507-515
91. Cosimelli M, Mancini R, Carpanese L, et al: Clinical safety and efficacy of 90yttrium resin microspheres alone in unresectable, heavily pre-treated colorectal liver metastases: Results of a phase II trial. In: Proceedings from the ASCO Annual Meeting; 2008; Chicago, IL
92. Mancini R., Carpanese L., Sciuto R., et al. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: Preliminary results on toxicity and response rates. In Vivo 20 6A (2006) 711-714
93. Sharma R.A., Van Hazel G.A., Morgan B., et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25 (2007) 1099-1106
94. Van Hazel G, Pavlakis N, Goldstein D: Selective internal radiation therapy (SIRT) plus systemic chemotherapy with irinotecan. A phase I dose escalation study. In: Proceedings from the ASCO Annual Meeting. ASCO GI Symposium, Hollywood, FL; 2005 (abstract 265)
95. Stubbs R.S. Portal hypertension and liver surgery following selective internal radiation therapy with 90Yttrium microspheres. J Clin Oncol 24 (2006) e15
96. Riaz A., Lewandowski R.J., Kulik L., et al. Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors. Q J Nucl Med Mol Imaging 53 (2009) 311-316
97. Geschwind J.F., Salem R., Carr B.I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 5 suppl 1 (2004) S194-S205
98. Salem R, Lewandowski RJ, Mulcahy MF, et al: Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology (in press)
99. Kulik L.M., Atassi B., van Holsbeeck L., et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94 (2006) 572-586
100. Benevento A., Boni L., Frediani L., et al. Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 74 (2000) 24-29
101. Rhee T.K., Lewandowski R.J., Liu D.M., et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience. Ann Surg 247 (2008) 1029-1035
102. Kennedy A.S., Dezarn W.A., McNeillie P., et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin Y-90-microspheres: Early results in 148 patients. Am J Clin Oncol Cancer Clin Trials 31 (2008) 271-279
103. King J., Quinn R., Glenn D.M., et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (2008) 921-929
104. Kalinowski M., Dressler M., Konig A., et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: A prospective single center study. Digestion 79 (2009) 137-142
105. Jakobs T.F., Hoffmann R.T., Fischer T., et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 19 (2008) 683-690
106. Coldwell D.M., Kennedy A.S., and Nutting C.W. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 69 (2007) 800-804
107. Ibrahim S.M., Mulcahy M.F., Lewandowski R.J., et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: Results from a pilot study. Cancer 113 (2008) 2119-2128
108. Viadana E., Bross I.D., and Pickren J.W. An autopsy study of some routes of dissemination of cancer of the breast. Br J Cancer 27 (1973) 336-340